Navigation Links
Nearly 40 Percent of GERD Patients Taking PPIs Experience Recurring Symptoms
Date:5/15/2008

- A majority of patients self-medicate with over-the-counter remedies to

relieve ongoing symptoms -

BETHESDA, Md., May 15 /PRNewswire/ -- Despite daily use of doctor-recommended proton pump inhibitors (PPIs) to control gastroesophageal reflux disease (GERD) symptoms, nearly 40 percent of patients who take them continue to experience breakthrough, which is a return of GERD symptoms, such as acid regurgitation and heartburn. These breakthrough symptoms lead more than half of GERD sufferers to use over-the-counter (OTC) remedies, according to a survey recently conducted by the American Gastroenterological Association (AGA) Institute.

The survey of 1,064 people with GERD found that approximately 56 percent of those who experienced breakthrough used an OTC treatment -- the majority using an antacid -- to manage breakthrough symptoms. Further, taking an OTC in addition to a PPI has become routine for these respondents. In fact, more than 70 percent have been using OTC medications for at least one year.

"The survey results show that people with GERD are not only using their prescribed PPI, but also are turning to over-the-counter remedies as a stop-gap when they have breakthrough symptoms," said John Inadomi, MD, associate professor of medicine, University of California, San Francisco.
Additional survey findings showed that:

-- More than 40 percent of respondents on a PPI who experience

breakthrough symptoms, report those symptoms occur two to four times

per week.

-- Respondents report breakthrough symptoms occur throughout the day,

sometimes multiple times per day. Sixty-five percent of GERD sufferers

experienced breakthrough at night and 28 percent report sleep

disruption because of their symptoms.

-- Among patients suffering from breakthrough symptoms, at least 50

percent are not fully satisfied with the specific symptom relief (e.g.,
'/>"/>

SOURCE AGA Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms
2. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
3. Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly $43 Million
4. Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel
5. USC receives nearly $27 million in funding for new stem cell research facility
6. Nearly one-third of US parents dont know what to expect of infants
7. Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer
8. Partnership for Prescription Assistance Celebrates Three Year Anniversary; Helps Nearly 5 Million Uninsured Patients Across United States
9. Sutter Health Donates Nearly $740,000 to Improve Community Health Care
10. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
11. Horizon Organic(R) Family Farmer Network Grows by Nearly 35 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Executive Leadership and CEO Announced for BiPar Sciences 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Cosmetic Use of Sculptra Now FDA Approved 54306 1Cosmetic Use of Sculptra Now FDA Approved 54306 2Cosmetic Use of Sculptra Now FDA Approved 54306 3Cosmetic Use of Sculptra Now FDA Approved 54306 4Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 1Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 2Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 3Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 1Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 2